Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Int J Infect Dis
; 97: 374-379, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32534142
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Comunitarias Adquiridas
/
Neumonía Bacteriana
/
Fluoroquinolonas
/
Moxifloxacino
/
Antibacterianos
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2020
Tipo del documento:
Article